A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)

被引：0

作者：

Weinblatt, Michael E. ^{[1
]}

Baranauskaite, Asta ^{[2
]}

Niebrzydowski, Jaroslaw ^{[3
]}

Dokoupilova, Eva ^{[4
]}

Zielinska, Agnieszka ^{[5
]}

Sitek-Ziolkowska, Karina ^{[6
]}

Jaworski, Janusz ^{[7
]}

Racewicz, Artur ^{[8
]}

Pileckyte, Margarita ^{[2
]}

Jedrychowicz-Rosiak, Krystyna ^{[9
]}

Zhdan, Vyacheslav ^{[10
]}

Cheong, Soo Yeon ^{[11
]}

Ghil, Jeehoon ^{[11
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Lithuanian Univ Hlth Sci, Kaunas, Lithuania

[3] Med Pro Familia, Gdynia, Poland

[4] Med Plus Sro, Uherske Hradiste, Czech Republic

[5] Med Pro Familia, Warsaw, Poland

[6] Med Pro Familia, Katowice, Poland

[7] Reumatika Ctr Reumatol, Warsaw, Poland

[8] Zdrowie Osteomed Sc, Bialystok, Poland

[9] Mazowieckie Ctr Badan Klin, Grodzisk Mazowiecki, Poland

[10] MV Sklifosovskyi Poltava Reg Clin Hosp, Poltava, Ukraine

[11] Samsung Bioepis Co Ltd, Inchon, South Korea

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
Gerd Burmester
Edit Drescher
Pawel Hrycaj
David Chien
Zhiying Pan
Stanley Cohen
Clinical Rheumatology, 2020, 39 : 3341 - 3352
[42] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
Gerd, Burmester
Edit, Drescher
Pawel, Hrycaj
David, Chien
Pan Zhiying
Stanley, Cohen
CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3341 - 3352
[43] Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Cohen, Stanley B.
Genovese, Mark C.
Choy, Ernest H.
Perez-Ruiz, Fernando
Pablos, Jose L.
Zhang, Nan
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[44] A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
Jani, Rajendrakumar H.
Gupta, Rajiv
Bhatia, Girish
Rathi, Gaurav
Kumar, Patnala Ashok
Sharma, Reena
Kumar, Uma
Gauri, Liyakat A.
Jadhav, Praveen
Bartakke, Girishchandra
Haridas, Vikram
Jain, Dinesh
Mendiratta, Sanjeev K.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (11) : 1157 - 1168
[45] LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Alten, Rieke
Genovese, Mark C.
Arai
Muniz, Rafael
Kellner, Herbert
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1135 - 1135
[46] A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (AbriladaT), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Fleischmann, Roy
Alvarez, Daniel
Bock, Amy
Cronenberger, Carol
Vranic, Ivana
Zhang, Wuyan
Alten, Rieke
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[47] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Jinmei Su
Mengtao Li
Lan He
Dongbao Zhao
Weiguo Wan
Yi Liu
Jianhua Xu
Jian Xu
Huaxiang Liu
Lindi Jiang
Huaxiang Wu
Xiaoxia Zuo
Cibo Huang
Xiumei Liu
Fen Li
Zhiyi Zhang
Xiangyuan Liu
Lingli Dong
Tianwang Li
Haiying Chen
Jingyang Li
Dongyi He
Xin Lu
Anbin Huang
Yi Tao
Yanyan Wang
Zhuoli Zhang
Wei Wei
Xiaofeng Li
Xiaofeng Zeng
BioDrugs, 2020, 34 : 381 - 393
[48] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Su, Jinmei
Li, Mengtao
He, Lan
Zhao, Dongbao
Wan, Weiguo
Liu, Yi
Xu, Jianhua
Xu, Jian
Liu, Huaxiang
Jiang, Lindi
Wu, Huaxiang
Zuo, Xiaoxia
Huang, Cibo
Liu, Xiumei
Li, Fen
Zhang, Zhiyi
Liu, Xiangyuan
Dong, Lingli
Li, Tianwang
Chen, Haiying
Li, Jingyang
He, Dongyi
Lu, Xin
Huang, Anbin
Tao, Yi
Wang, Yanyan
Zhang, Zhuoli
Wei, Wei
Li, Xiaofeng
Zeng, Xiaofeng
BIODRUGS, 2020, 34 (03) : 381 - 393
[49] Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
Gerd Burmester
Edit Drescher
Pawel Hrycaj
David Chien
Zhiying Pan
Stanley Cohen
Clinical Rheumatology, 2020, 39 : 3527 - 3527
[50] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld, FC
Weisman, MH
Kavanaugh, AF
Cohen, SB
Pavelka, K
van Vollenhoven, R
Sharp, J
Perez, JL
Spencer-Green, GT
ARTHRITIS AND RHEUMATISM, 2006, 54 (01): : 26 - 37

← 1 2 3 4 5 →